These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 28358507)

  • 1. Protein Degradation via CRL4
    Hansen JD; Condroski K; Correa M; Muller G; Man HW; Ruchelman A; Zhang W; Vocanson F; Crea T; Liu W; Lu G; Baculi F; LeBrun L; Mahmoudi A; Carmel G; Hickman M; Lu CC
    J Med Chem; 2018 Jan; 61(2):492-503. PubMed ID: 28358507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel cereblon modulator recruits GSPT1 to the CRL4(CRBN) ubiquitin ligase.
    Matyskiela ME; Lu G; Ito T; Pagarigan B; Lu CC; Miller K; Fang W; Wang NY; Nguyen D; Houston J; Carmel G; Tran T; Riley M; Nosaka L; Lander GC; Gaidarova S; Xu S; Ruchelman AL; Handa H; Carmichael J; Daniel TO; Cathers BE; Lopez-Girona A; Chamberlain PP
    Nature; 2016 Jul; 535(7611):252-7. PubMed ID: 27338790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.).
    Gandhi AK; Kang J; Havens CG; Conklin T; Ning Y; Wu L; Ito T; Ando H; Waldman MF; Thakurta A; Klippel A; Handa H; Daniel TO; Schafer PH; Chopra R
    Br J Haematol; 2014 Mar; 164(6):811-21. PubMed ID: 24328678
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Cereblon Modulator (CC-220) with Improved Degradation of Ikaros and Aiolos.
    Matyskiela ME; Zhang W; Man HW; Muller G; Khambatta G; Baculi F; Hickman M; LeBrun L; Pagarigan B; Carmel G; Lu CC; Lu G; Riley M; Satoh Y; Schafer P; Daniel TO; Carmichael J; Cathers BE; Chamberlain PP
    J Med Chem; 2018 Jan; 61(2):535-542. PubMed ID: 28425720
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL.
    Hagner PR; Man HW; Fontanillo C; Wang M; Couto S; Breider M; Bjorklund C; Havens CG; Lu G; Rychak E; Raymon H; Narla RK; Barnes L; Khambatta G; Chiu H; Kosek J; Kang J; Amantangelo MD; Waldman M; Lopez-Girona A; Cai T; Pourdehnad M; Trotter M; Daniel TO; Schafer PH; Klippel A; Thakurta A; Chopra R; Gandhi AK
    Blood; 2015 Aug; 126(6):779-89. PubMed ID: 26002965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective Degradation of GSPT1 by Cereblon Modulators Identified via a Focused Combinatorial Library.
    Powell CE; Du G; Che J; He Z; Donovan KA; Yue H; Wang ES; Nowak RP; Zhang T; Fischer ES; Gray NS
    ACS Chem Biol; 2020 Oct; 15(10):2722-2730. PubMed ID: 32865967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CC-90009, a novel cereblon E3 ligase modulator, targets acute myeloid leukemia blasts and leukemia stem cells.
    Surka C; Jin L; Mbong N; Lu CC; Jang IS; Rychak E; Mendy D; Clayton T; Tindall E; Hsu C; Fontanillo C; Tran E; Contreras A; Ng SWK; Matyskiela M; Wang K; Chamberlain P; Cathers B; Carmichael J; Hansen J; Wang JCY; Minden MD; Fan J; Pierce DW; Pourdehnad M; Rolfe M; Lopez-Girona A; Dick JE; Lu G
    Blood; 2021 Feb; 137(5):661-677. PubMed ID: 33197925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN.
    Sievers QL; Petzold G; Bunker RD; Renneville A; Słabicki M; Liddicoat BJ; Abdulrahman W; Mikkelsen T; Ebert BL; Thomä NH
    Science; 2018 Nov; 362(6414):. PubMed ID: 30385546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CC-90009: A Cereblon E3 Ligase Modulating Drug That Promotes Selective Degradation of GSPT1 for the Treatment of Acute Myeloid Leukemia.
    Hansen JD; Correa M; Alexander M; Nagy M; Huang D; Sapienza J; Lu G; LeBrun LA; Cathers BE; Zhang W; Tang Y; Ammirante M; Narla RK; Piccotti JR; Pourdehnad M; Lopez-Girona A
    J Med Chem; 2021 Feb; 64(4):1835-1843. PubMed ID: 33591756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting Ikaros and Aiolos: reviewing novel protein degraders for the treatment of multiple myeloma, with a focus on iberdomide and mezigdomide.
    Liu Y; Mo CC; Hartley-Brown MA; Sperling AS; Midha S; Yee AJ; Bianchi G; Piper C; Tattersall A; Nadeem O; Laubach JP; Richardson PG
    Expert Rev Hematol; 2024 Aug; 17(8):445-465. PubMed ID: 39054911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of Potent, Selective, and Orally Bioavailable Small-Molecule GSPT1/2 Degraders from a Focused Library of Cereblon Modulators.
    Nishiguchi G; Keramatnia F; Min J; Chang Y; Jonchere B; Das S; Actis M; Price J; Chepyala D; Young B; McGowan K; Slavish PJ; Mayasundari A; Jarusiewicz JA; Yang L; Li Y; Fu X; Garrett SH; Papizan JB; Kodali K; Peng J; Pruett Miller SM; Roussel MF; Mullighan C; Fischer M; Rankovic Z
    J Med Chem; 2021 Jun; 64(11):7296-7311. PubMed ID: 34042448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A genome-scale CRISPR-Cas9 screening in myeloma cells identifies regulators of immunomodulatory drug sensitivity.
    Liu J; Song T; Zhou W; Xing L; Wang S; Ho M; Peng Z; Tai YT; Hideshima T; Anderson KC; Cang Y
    Leukemia; 2019 Jan; 33(1):171-180. PubMed ID: 30026574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trends in Neosubstrate Degradation by Cereblon-Based Molecular Glues and the Development of Novel Multiparameter Optimization Scores.
    Szewczyk SM; Verma I; Edwards JT; Weiss DR; Chekler ELP
    J Med Chem; 2024 Jan; 67(2):1327-1335. PubMed ID: 38170610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. UBE2G1 governs the destruction of cereblon neomorphic substrates.
    Lu G; Weng S; Matyskiela M; Zheng X; Fang W; Wood S; Surka C; Mizukoshi R; Lu CC; Mendy D; Jang IS; Wang K; Marella M; Couto S; Cathers B; Carmichael J; Chamberlain P; Rolfe M
    Elife; 2018 Sep; 7():. PubMed ID: 30234487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural basis of lenalidomide-induced CK1α degradation by the CRL4(CRBN) ubiquitin ligase.
    Petzold G; Fischer ES; Thomä NH
    Nature; 2016 Apr; 532(7597):127-30. PubMed ID: 26909574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p97/VCP promotes degradation of CRBN substrate glutamine synthetase and neosubstrates.
    Nguyen TV; Li J; Lu CJ; Mamrosh JL; Lu G; Cathers BE; Deshaies RJ
    Proc Natl Acad Sci U S A; 2017 Apr; 114(14):3565-3571. PubMed ID: 28320958
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cereblon modulator iberdomide induces degradation of the transcription factors Ikaros and Aiolos: immunomodulation in healthy volunteers and relevance to systemic lupus erythematosus.
    Schafer PH; Ye Y; Wu L; Kosek J; Ringheim G; Yang Z; Liu L; Thomas M; Palmisano M; Chopra R
    Ann Rheum Dis; 2018 Oct; 77(10):1516-1523. PubMed ID: 29945920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins.
    Lu G; Middleton RE; Sun H; Naniong M; Ott CJ; Mitsiades CS; Wong KK; Bradner JE; Kaelin WG
    Science; 2014 Jan; 343(6168):305-9. PubMed ID: 24292623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Translation Termination Factor GSPT1 Is a Phenotypically Relevant Off-Target of Heterobifunctional Phthalimide Degraders.
    Ishoey M; Chorn S; Singh N; Jaeger MG; Brand M; Paulk J; Bauer S; Erb MA; Parapatics K; Müller AC; Bennett KL; Ecker GF; Bradner JE; Winter GE
    ACS Chem Biol; 2018 Mar; 13(3):553-560. PubMed ID: 29356495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of a First-in-Class Degrader for Nuclear Receptor Binding SET Domain Protein 2 (NSD2) and Ikaros/Aiolos.
    Meng F; Xu C; Park KS; Kaniskan HÜ; Wang GG; Jin J
    J Med Chem; 2022 Aug; 65(15):10611-10625. PubMed ID: 35895319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.